Dual treatment with lopinavir-ritonavir plus lamivudine versus
triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a
second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1
viral suppression (OLE): a randomised, open-label, non-inferiority trial.
Arribas JR, Girard PM, Landman R, et al
Lancet Infect Dis. 2015 Jun 5.
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
A simplified combination antiretroviral therapy regimen
enhances adherence, treatment satisfaction and quality of life: results of a
randomized clinical trial.
Langebeek N,
Sprenger H, Gisolf E, et al
HIV Med.
2013 Nov 11.
Abstract
Ritonavir-boosted lopinavir plus nucleoside or nucleotide
reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus
raltegravir for treatment of HIV-1 infection in adults with virological
failure of a standard first-line ART regimen (SECOND-LINE): a randomised,
open-label, non-inferiority study.
SECOND-LINE Study
Group, Boyd MA, Kumarasamy N, Moore CL, et al
Lancet. 2013 Jun 15;381(9883):2091-9.
Abstract
Lopinavir/ritonavir (LPV/r) Combined with Raltegravir (RAL) or
Tenofovir/Emtricitabine (TDF/FTC) in Antiretroviral (ARV)-naïve Subjects:
96-Week Results of the PROGRESS Study.
Reynes J, Trinh R, Pulido F, et al
AIDS Res Hum Retroviruses.
2012 Jun 25.
Abstract
Examination of Noninferiority, Safety, and Tolerability of Lopinavir/ritonavir
and Raltegravir Compared
with Lopinavir/ritonavir and Tenofovir/ Emtricitabine in Antiretroviral-Naïve
Subjects: The PROGRESS Study, 48-Week Results.
Reynes J, Lawal A, Pulido F,
Soto-Malave R,
et al
HIV Clin Trials.
2011 Sep-Oct;12(5):255-67.
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected
patients receiving once-daily
atazanavir/ritonavir
or twice-daily lopinavir/ritonavir, each in combination with tenofovir
disoproxil fumarate
and emtricitabine.
Uy J, Yang R, Wirtz V, et al
AIDS Care.
2011 Jul 7.
Abstract
FULL-TEXT PDF ARTICLE
High
efficacy of lopinavir/r-based second-line antiretroviral treatment after 24
months of follow up at
ESTHER/Calmette Hospital in Phnom Penh, Cambodia.
Ferradini L, Ouk V, Segeral O,
et al
J Int AIDS Soc. 2011 Mar
26;14(1):14
Paper
A WEEK-IN-REVIEW FEATURED REPORT
Short Communication: Comparable Safety and Efficacy
with Once-Daily Versus
Twice-Daily Dosing of Lopinavir/Ritonavir
Tablets with Emtricitabine + Tenofovir DF
in Antiretroviral-Naïve, HIV
Type 1-Infected
Subjects: 96 Week Final Results of
the Randomized
Trial M05-730.
González-García J, Cohen D, Johnson M, et al
AIDS Res Hum Retroviruses.
2010 Jul 30
Abstract |
LPV/Amprenavir
LPN/r
Adult/Adol Journal Main Page
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader